{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T14:07:55Z","timestamp":1791122875695,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"German ministry of education and research BMBF","award":["01KI1006I"],"award-info":[{"award-number":["01KI1006I"]}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB1009B2"],"award-info":[{"award-number":["SFB1009B2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DFG Lu477\/23-1"],"award-info":[{"award-number":["DFG Lu477\/23-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"German Center for Infection Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.antiviral.2017.03.024","type":"journal-article","created":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T23:01:02Z","timestamp":1491087662000},"page":"178-184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["The MEK-inhibitor CI-1040 displays a broad anti-influenza virus activity in\u00a0vitro and provides a prolonged treatment window compared to standard of care in\u00a0vivo"],"prefix":"10.1016","volume":"142","author":[{"given":"Emanuel","family":"Haasbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christin","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Ehrhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Pleschka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Planz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2017.03.024_bib1","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/135965350701200S04.1","article-title":"Influenza virus susceptibility and resistance to oseltamivir","volume":"12","author":"Aoki","year":"2007","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2017.03.024_bib2","first-page":"583","article-title":"Influenza activity - United States, 2014\u201315 season and composition of the 2015\u201316 influenza vaccine","volume":"64","author":"Appiah","year":"2015","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.antiviral.2017.03.024_bib3","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1093\/infdis\/jit554","article-title":"The neuraminidase inhibitor oseltamivir is effective against A\/Anhui\/1\/2013 (H7N9) influenza virus in a mouse model of acute respiratory distress syndrome","volume":"209","author":"Baranovich","year":"2014","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.antiviral.2017.03.024_bib4","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1016\/j.bmcl.2008.10.054","article-title":"The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901","volume":"18","author":"Barrett","year":"2008","journal-title":"Bioorg Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2017.03.024_bib5","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jama.295.8.joc60020","article-title":"Adamantane resistance among influenza A viruses isolated early during the 2005\u20132006 influenza season in the United States","volume":"295","author":"Bright","year":"2006","journal-title":"Jama"},{"key":"10.1016\/j.antiviral.2017.03.024_bib6","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES2015.20.4.21023","article-title":"Start of the 2014\/15 influenza season in Europe: drifted influenza A(H3N2) viruses circulate as dominant subtype","volume":"20","author":"Broberg","year":"2015","journal-title":"Euro Surveill."},{"key":"10.1016\/j.antiviral.2017.03.024_bib7","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.antiviral.2011.08.002","article-title":"Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in\u00a0vitro and in\u00a0vivo","volume":"92","author":"Droebner","year":"2011","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2017.03.024_bib8","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1073\/pnas.0308352100","article-title":"Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome","volume":"101","author":"Fouchier","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2017.03.024_bib9","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.2174\/092986709789104984","article-title":"Potential targets and their relevant inhibitors in anti-influenza fields","volume":"16","author":"Gong","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.antiviral.2017.03.024_bib10","doi-asserted-by":"crossref","first-page":"b5106","DOI":"10.1136\/bmj.b5106","article-title":"Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis","volume":"339","author":"Jefferson","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.antiviral.2017.03.024_bib11","first-page":"CD008965","article-title":"Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children","volume":"4","author":"Jefferson","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.antiviral.2017.03.024_bib12","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1146\/annurev-med-010714-112311","article-title":"H7N9: preparing for the unexpected in influenza","volume":"66","author":"Jernigan","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.antiviral.2017.03.024_bib13","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(04)16934-1","article-title":"Resistant influenza A viruses in children treated with oseltamivir: descriptive study","volume":"364","author":"Kiso","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2017.03.024_bib14","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/QCO.0b013e3283199797","article-title":"The potential impact of neuraminidase inhibitor resistant influenza","volume":"21","author":"Lackenby","year":"2008","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2017.03.024_bib15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0166-3542(00)00123-6","article-title":"The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A\/Hong Kong\/156\/97 (H5N1) and A\/Hong Kong\/1074\/99 (H9N2) influenza viruses","volume":"48","author":"Leneva","year":"2000","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2017.03.024_bib16","doi-asserted-by":"crossref","first-page":"5281","DOI":"10.1200\/JCO.2005.14.415","article-title":"Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies","volume":"23","author":"Lorusso","year":"2005","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.antiviral.2017.03.024_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkp161","article-title":"Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy","volume":"64","author":"Ludwig","year":"2009","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2017.03.024_bib18","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1515\/BC.2011.121","article-title":"Disruption of virus-host cell interactions and cell signaling pathways as an anti-viral approach against influenza virus infections","volume":"392","author":"Ludwig","year":"2011","journal-title":"Biol. Chem."},{"key":"10.1016\/j.antiviral.2017.03.024_bib19","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1471-4914(02)00010-2","article-title":"Influenza-virus-induced signaling cascades: targets for antiviral therapy?","volume":"9","author":"Ludwig","year":"2003","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.antiviral.2017.03.024_bib20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0014-5793(04)00108-5","article-title":"MEK inhibition impairs influenza B virus propagation without emergence of resistant variants","volume":"561","author":"Ludwig","year":"2004","journal-title":"FEBS Lett."},{"key":"10.1016\/j.antiviral.2017.03.024_bib21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1057\/jphp.2011.51","article-title":"Lessons from SARS and H1N1\/A: employing a WHO-WTO forum to promote optimal economic-public health pandemic response","volume":"33","author":"Mackey","year":"2012","journal-title":"J.\u00a0Public Health Policy"},{"key":"10.1016\/j.antiviral.2017.03.024_bib22","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/1743-422X-4-134","article-title":"Higher polymerase activity of a human influenza virus enhances activation of the hemagglutinin-induced Raf\/MEK\/ERK signal cascade","volume":"4","author":"Marjuki","year":"2007","journal-title":"Virol. J."},{"key":"10.1016\/j.antiviral.2017.03.024_bib23","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1111\/j.1462-5822.2007.00902.x","article-title":"Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-kappaB-inhibiting activity","volume":"9","author":"Mazur","year":"2007","journal-title":"Cell Microbiol."},{"key":"10.1016\/j.antiviral.2017.03.024_bib24","doi-asserted-by":"crossref","first-page":"6427","DOI":"10.1016\/j.vaccine.2011.06.113","article-title":"Response to the 2009 pandemic: effect on influenza control in wealthy and poor countries","volume":"29","author":"Monto","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2017.03.024_bib25","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00445-13","article-title":"H7N9 avian influenza A virus and the perpetual challenge of potential human pandemicity","volume":"4","author":"Morens","year":"2013","journal-title":"MBio"},{"key":"10.1016\/j.antiviral.2017.03.024_bib26","doi-asserted-by":"crossref","first-page":"10556","DOI":"10.1128\/JVI.00570-14","article-title":"H7N9 and other pathogenic avian influenza viruses elicit a three-pronged transcriptomic signature that is reminiscent of 1918 influenza virus and is associated with lethal outcome in mice","volume":"88","author":"Morrison","year":"2014","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2017.03.024_bib27","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/jac\/dkq100","article-title":"Targeting pandemic influenza: a primer on influenza antivirals and drug resistance","volume":"65","author":"Moss","year":"2010","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2017.03.024_bib28","doi-asserted-by":"crossref","first-page":"6639","DOI":"10.1038\/sj.onc.1207883","article-title":"Lung-specific expression of active Raf kinase results in increased mortality of influenza A virus-infected mice","volume":"23","author":"Olschlager","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.antiviral.2017.03.024_bib29","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S1473-3099(11)70295-X","article-title":"Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis","volume":"12","author":"Osterholm","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2017.03.024_bib30","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.antiviral.2013.04.008","article-title":"Development of cellular signaling pathway inhibitors as new antivirals against influenza","volume":"98","author":"Planz","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2017.03.024_bib31","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1128\/JVI.75.10.4871-4877.2001","article-title":"MEK-specific inhibitor U0126 blocks spread of Borna disease virus in cultured cells","volume":"75","author":"Planz","year":"2001","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2017.03.024_bib32","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/35060098","article-title":"Influenza virus propagation is impaired by inhibition of the Raf\/MEK\/ERK signalling cascade","volume":"3","author":"Pleschka","year":"2001","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.antiviral.2017.03.024_bib33","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.virusres.2011.09.024","article-title":"Prospects for controlling future pandemics of influenza","volume":"162","author":"Robertson","year":"2011","journal-title":"Virus Res."},{"key":"10.1016\/j.antiviral.2017.03.024_bib34","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/10533","article-title":"Blockade of the MAP kinase pathway suppresses growth of colon tumors in\u00a0vivo","volume":"5","author":"Sebolt-Leopold","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2017.03.024_bib35","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/10837450500299636","article-title":"Increased dissolution rate and bioavailability through comicronization with microcrystalline cellulose","volume":"10","author":"Spence","year":"2005","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.antiviral.2017.03.024_bib36","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/1471-2334-11-134","article-title":"Systematic review of influenza resistance to the neuraminidase inhibitors","volume":"11","author":"Thorlund","year":"2011","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.antiviral.2017.03.024_bib37","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1086\/432008","article-title":"Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A\/Vietnam\/1203\/04 influenza virus in mice","volume":"192","author":"Yen","year":"2005","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.antiviral.2017.03.024_bib38","first-page":"241","article-title":"The 2009 pandemic influenza virus: where did it come from, where is it now, and where is it going?","volume":"370","author":"York","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354217300608?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354217300608?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:26:53Z","timestamp":1759062413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354217300608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":38,"alternative-id":["S0166354217300608"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.03.024","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The MEK-inhibitor CI-1040 displays a broad anti-influenza virus activity in\u00a0vitro and provides a prolonged treatment window compared to standard of care in\u00a0vivo","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.03.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}